Mar 1, 2021
CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION
Jan 21, 2021
CORMEDIX INC. TO BEGIN TRADING ON THE NASDAQ STOCK EXCHANGE
Nov 18, 2020
CORMEDIX INC. ANNOUNCES FDA DECISION THAT ADVISORY COMMITTEE MEETING FOR NEW DRUG APPLICATION FOR DEFENCATH IS NOT NEEDED
Nov 5, 2020
CORMEDIX INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Nov 2, 2020
CorMedix Appoints Greg Duncan to its Board of Directors
Oct 29, 2020
CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5
Oct 8, 2020
CorMedix to Participate in BIO Investor Forum Digital
Sep 17, 2020
Cormedix Appoints Paulo Costa to its Board of Directors
Sep 9, 2020
CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Aug 31, 2020
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DEFENCATH
Aug 10, 2020
CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Aug 4, 2020
CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10
Jul 28, 2020
CorMedix Announces Pricing of $20M Public Offering of Common Stock
Jul 27, 2020
CorMedix Announces Proposed Public Offering of Common Stock
Jul 8, 2020
CORMEDIX INC. REPORTS SUBMISSION OF DEFENCATH™ NEW DRUG APPLICATION
May 11, 2020
CORMEDIX INC. REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 11, 2020
CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER
May 6, 2020
CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®
Apr 22, 2020
CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program
Mar 17, 2020
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
